Profusa, Inc. Provides Strategy Overview and Business Update for Investors

Core Insights - Profusa, Inc. has recently gone public on the Nasdaq under the ticker PFSA and is focused on advancing its personalized biochemistry technology platform for clinical applications [1][2] - The company has outlined a growth strategy based on five pillars: revenue growth and pipeline development, AI infrastructure, clinical and regulatory pathways, financial structure, and operational scaling [2] Revenue Growth and Pipeline Development - Profusa is on track to generate revenue from research use applications of its technology, which will enhance commercial operations and expand the capabilities of its platform [3] - Future personalized healthcare applications being pursued include lactate, carbon dioxide, sodium, and ethanol [3] Clinical and Regulatory Pathways - The company is progressing towards the European launch of its Lumee™ platform for tissue oxygen monitoring, with a target commercial launch in Q1 2026 [4] - The global addressable market for tissue oxygen monitoring is estimated at approximately $10 billion, with around 300,000 endovascular procedures occurring annually in Europe [4] Continuous Glucose Monitoring - Profusa's continuous glucose monitoring platform targets a global addressable market of over 500 million patients, with human validation data expected to be published soon [5] - Pivotal studies for this platform are anticipated to commence in late 2026, aiming for commercialization by mid-2027 [5] Financial Structure and Strategies - The company has secured a $100 million ELOC facility to support its growth phase and is implementing a strategic treasury plan focused on digital investment [6] - This financial strategy aims to enhance shareholder value and attract open market investors [6] Scale of Operations - Profusa is expanding its operational capabilities to prepare for scaling its business and executing its vision [7] Commitment to Innovation - The company is dedicated to delivering its technology to the clinical community, addressing the needs of patients with chronic diseases and contributing to personalized healthcare [8] - Profusa's management team is focused on achieving technological and financial milestones to enhance shareholder value [9]